팜젠사이언스

004720KOSPI

45.5 / 100

Reference Date: 2026-09-08

Financial Score20.0 / 40

News Sentiment12.5 / 25

Momentum3.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 7.7% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Palmgen Science operates in pharmaceuticals, healthcare, and real estate leasing, achieving 16.54 billion KRW in pharmaceutical sales and 650 million KRW in healthcare sales in 2025. Key products include Esomax (for digestive disorders), Bardifin (hypertension treatment), and Kvasitin (hyperlipidemia treatment), with the company enhancing competitiveness through new drug development and quality improvements.

Number of Employees

229people

Average Salary

71.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

0.47Industry Average 1.207.0Point

Half of industry avg (excellent)

ROE

-58.95Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

10.55Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20251.0 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲1.9% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼13.6% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -18.4% (declining, 3yr)

Detailed News Sentiment

2 totalPositive 0Neutral 2Negative 0Average Sentiment Score 50

Neutral
알에프바이오, 말레이시아 AMSC 참가…유스필 글로벌 학술 마케팅 강....
알에프바이오의 글로벌 학술 마케팅 활동이 팜젠사이언스와 직접적인 연관성이 낮아 팜젠사이언스에 대한 직접적인 영향은 제한적이다.
Neutral
알에프바이오, 'AMSC 말레이시아' 참가…"동남아 마케팅 강화"
AlrfBio's participation in AMSC Malaysia event focuses on regional marketing expertise, impacting general industry rather than directly affecting 팜젠사이언스.

Detailed Momentum

52-week position1.0Point

Near 52w low (16%, downtrend)

Current 3,020Won52-week high 4,59052-week low 2,710

1-month return1.0Point

1m -7.65% (falling)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral반기보고서 (2026.06)2026-08-14